302964-02-9

Basic information

• Product Name: 2-N-BOC-AMINO-THIAZOLE-5-CARBOXYLIC ACID
• Synonyms: 2-[(tert-butoxycarbonyl)amino]-1,3-thiazole-5-carboxylic acid;2-Boc-aminothiazole-5-carboxylic acid;2-N-Boc-AMino-thiazole-5-carboxylicacid/2-(tert-butoxycarbonylaMino)thiazole-5-carboxylicacid;5-Thiazolecarboxylic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-;2-(tert-Butoxycarbonylamino)thiazole-5-carboxylic Acid
• CAS NO: 302964-02-9
• Molecular Formula: C₉H₁₂N₂O₄S
• Molecular Weight: 244.27
• Product Categories: CHIRAL CHEMICALS
• Mol File: 302964-02-9.mol

Chemical Properties

• Melting Point: 220-222°(dec)
• Appearance: /
• Density: 1.406 g/cm³
• Refractive Index: 1.602
• Storage Temp.: 2-8°C
• PKA: 5.53±0.70(Predicted)
• CAS DataBase Reference: 2-N-BOC-AMINO-THIAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-N-BOC-AMINO-THIAZOLE-5-CARBOXYLIC ACID(302964-02-9)
• EPA Substance Registry System: 2-N-BOC-AMINO-THIAZOLE-5-CARBOXYLIC ACID(302964-02-9)

Safety Data

• Hazard Codes: Xi
• Statements: 43-36/37/38
• Safety Statements: 36/37-36-26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 302964-02-9(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C9H12N2O4S/c1-9(2,3)15-8(14)11-7-10-4-5(16-7)6(12)13/h4H,1-3H3,(H,12,13)(H,10,11,14)

Upstream product

• 40283-46-3 2-aminothiazole-5-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 745078-03-9 2-tert-butoxycarbonylamino-thiazole-5-carboxylic acid methyl ester 
• 32955-21-8 2-amino-thiazole-5-carboxylic acid ethyl ester 
• 302964-01-8 ethyl 2-[(tert-butoxycarbonyl)amino]-1.3-thiazole-5-carboxylate 

Downstream Products

• 1029088-56-9 tert-butyl 5-(4-p-tolylthiazol-2-ylcarbamoyl)thiazol-2-ylcarbamate 
• 731018-54-5 2-(tert-butoxycarbonyl)amino-5-fluorothiazole 
• 1160297-29-9 tert-butyl 5-(2-chloro-6-(methyl-d3)phenylcarbamoyl)thiazol-2-ylcarbamate 
• 302964-06-3 [5-(2-chloro-6-methylphenylcarbamoyl)thiazol-2-yl]-carbamic acid tert-butyl ester 
• 302957-97-7 [5-[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-thiazolyl]carbamic acid-1,1-dimethylethyl ester 
• 934193-04-1 [5-[[(2,6-dimethylphenyl)amino]carbonyl]-2-thiazolyl]carbamic acid 1,1-dimethylethyl ester 
• 302964-20-1 2-tert-butoxycarbonylamino-1,3-thiazole-5-carboxylic acid chloride 

Relevant articles and documents

A convenient new and efficient commercial synthetic route for dasatinib (Sprycel)

A new and efficient synthetic route for dual-Src/Abl kinase inhibitor dasatinib (Sprycel), an anticancer drug, is described. This commercially viable process yields dasatinib monohydrate free of potential impurities with consistent yield of 68% in route A and 61% in route B with HPLC purity >99.80% over four stages.

Protein kinase inhibitor and use thereof

The present invention provides a compound of formula 1 having an activity of inhibiting protein kinase and its use.

Scalable and impurity-free process for dasatinib: Src and BCR-Abl inhibitor

An efficient, telescopic, impurity-free and scalable process for Bcr-Abl and Src family tyrosine kinase inhibitor for synthesis of Dasatinib with high yield and purity is described.

AN IMPROVED PROCESS FOR THE PREPARATION OF DASATINIB POLYMORPH

The present invention is related to an improved process for the preparation of dasatinib anhydrous crystalline Neat form N-6 with high purity and high yield. The present invention also relates to purification of dasatinib crystalline Neat form N-6.

Dasatinib derivative with anti-tumor activity and application thereof

The invention belongs to the technical field of medicine chemistry and particularly relates to a dasatinib derivative with anti-tumor activity and application thereof. The dasatinib derivative provided by the invention has a very good inhibition effect on tyrosine kinase and has a very good application prospect for developing in the anti-tumor aspect.

METHOD OF MAKING AZAINDAZOLE DERIVATIVES

Disclosed are methods, reagents, and intermediates useful for making azaindazole derivatives, which may be used to modulate Glucokinase. The disclosed methods and materials are generally useful for making halo-esters and sulfonyl-substituted compounds.

PROCESS FOR THE PRODUCTION OF 2-AMINO-5-FLUOROTHIAZOLE

A process for the production of fluorinated compound represented by the formula (I): or salts thereof wherein R1 and R2 are the same or different and each is selected from the group consisting of a hydrogen atom, a carbonyl group, a

A new and efficient preparation of 2-aminothiazole-5-carbamides: Applications to the synthesis of the anti-cancer drug dasatinib

A new and efficient method has been developed for the synthesis of 2-amino-N-(-(2-chloro-6-methylphenyl)-thiazole-5-carboxamide. The new method involves a chemoselective α-bromination of β-ethoxyacrylamide followed by a one-pot treatment with thiourea to give the desired 2-aminothiazole-5-carboxylamide in excellent yield. Application of this new method to the efficient synthesis of the anti-cancer drug dasatinib was demonstrated.

FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF

Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including metabolic and inflammatory and immune diseases or disorders, ha

NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.